MindMed And Other Psychedelic Stocks Brace For FDA's Decision On MDMA Therapy
- The FDA's decision on MDMA therapy for PTSD is imminent, impacting MindMed investors and the psychedelic medicine industry. An FDA advisory committee voted against approving MDMA therapy, causing market volatility and uncertainty for psychedelic stocks. Major psychedelic stocks like MindMed have the fundamentals and growing FDA support to withstand a negative FDA decision on MDMA therapy.
- 08/07/2024
|
3 Psychedelic Stocks to Ride to the Moon and Beyond
- The value of the psychedelic market is expected to approximately triple over the next few years. While not a large market in absolute terms, that growth potential will create many winning stocks.
- 07/06/2024
|
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
- The biotech industry has fallen on hard times over the last few years, no thanks to venture capital drying up, tighter regulatory conditions and the harsh reality of the post-pandemic healthcare environment. As a result, biotech breakthrough stocks fell out of favor with investors and were among the worst performers in the stock market.
- 07/04/2024
|
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
- NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference being held on June 27, 2024. A webcast of the fireside chat will be accessible on MindMed's Investor Relations website starting on June 27,.
- 06/21/2024
|
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
- NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the completion of the End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of MM120 (lysergic acid diethylamide [LSD] D-tartrate) into pivotal trials for the treatment of adults with GAD. “Following a constructive En.
- 06/20/2024
|
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024
- As the main stock indices like the S&P 500 and Nasdaq continue to climb, penny stocks are becoming attractive for those seeking significant returns. Despite their reputation for extreme price fluctuations and high risk, they offer the potential for impressive gains, especially in a bull market.
- 06/18/2024
|
Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year?
- Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.
- 06/14/2024
|
Are Medical Stocks Lagging Mind Medicine MindMed (MNMD) This Year?
- Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.
- 05/29/2024
|
MindMed to Participate in June Conferences
- NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will participate in the following conferences: BIO International Convention 2024 Panel Name: Challenging Biotech's One-Track Mind When it Comes to Neuropsychiatric Drug Innovation Date and Time: Tuesday, June 4, 2024 at 4:15.
- 05/28/2024
|
The Time Traveler's Portfolio: 3 Stocks to Buy Now for Massive Returns by 2034
- Imagine you could go back in time to find last decade's long-term stocks to buy. Nvidia (NASDAQ: NVDA ) returned nearly 20,000% growth since 2014.
- 05/23/2024
|
Psychedelics Closer To Commercialization; Compass Far And Away The Leader
- Regulatory risk in the psychedelic industry is decreasing, which is a positive sign for investors. Institutional investors are becoming more willing to invest in leading psychedelic companies through private placements.
- 05/23/2024
|
Top Russell 2000 Picks: 3 Small-Cap Stocks to Scoop Up This May
- The stock market continues to question whether a large cap dominance — especially that from The Magnificent Seven — is indeed the best way to invest. While investing in large cap firms is undoubtedly a good strategy, there are plenty of top Russell 2000 stocks to buy.
- 05/10/2024
|
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
- Biotech breakthrough stocks, along with the sector overall, faced significant challenges over the past two years, with venture capital drying up, shifts in the post-pandemic healthcare landscape and tighter regulatory conditions squeezing already-thin margins. However, 2024 may herald a resurgence for biotech stocks, spurred by an FDA approval spree throughout 2023.
- 05/09/2024
|
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
- NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented data from MMED008, its Phase 2b study of MM120 (lysergide d-tartrate) in the treatment of GAD in adults. MM120 demonstrated clinically and statistically significant efficacy compared to placebo at its primary week 4 and secondary week 12 timepoints. The study was presen.
- 05/04/2024
|
The Top 3 Small-Cap Stocks to Buy in April 2024
- Higher interest rates, pricier debt and an overemphasis on mega-caps over the past year mean that top small-cap stocks have played second fiddle to big-name giants like Nvidia (NASDAQ: NVDA ). But tides seem to be turning as investors increasingly seek diversification away from a handful of high-multiple tech stocks and toward a more diverse array of product types, operational structures and size — all of which small-cap stocks have in spades.
- 04/25/2024
|
MindMed to Present at Upcoming May Medical Conferences
- NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences: American Psychiatric Association (.
- 04/25/2024
|
This Small-Cap Stock Is Up 140% This Year and Here's Why It Can Go Even Higher
- Mind Medicine has an exciting treatment option for generalized anxiety disorder -- MM120. In clinical trials, MM120 reduced anxiety in patients after just a single dose.
- 04/25/2024
|
MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why
- MindMed's (MNMD) progress with the development of its lead candidate MM120 for treating generalized anxiety disorder has been encouraging, leading the stock to rise during this time.
- 04/08/2024
|
Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data
- Mind Medicine (MindMed) Inc. achieved positive results from phase 2b MMED008 study using MM-120 for the treatment of patients with generalized anxiety disorder. End-of-phase 2 meeting with the FDA for MM-120 program for GAD 1st half of 2024 and phase 3 trial initiation expected 2nd half of 2024. The global generalized anxiety disorder treatment market is expected to reach $4.26 billion by 2033.
- 04/04/2024
|
MindMed to Present at Upcoming April Medical Conferences
- NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that COVID has had on the epidemiology of Generalized Anxiety Disorder at two upcoming medical conferences: European Psychiatric Association (EPA) 2024 Congress Title: Prevalence of Generalized Anx.
- 04/02/2024
|
MindMed Announces Voluntary Delisting from Cboe Canada
- NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has elected to voluntarily delist its common shares from Cboe Canada, effective at the close of markets on April 10, 2024, and the notice of voluntary delisting has been accepted by Cboe Canada. MindMed's common shares will continue to be lis.
- 04/01/2024
|
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
- NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will host one on one investor meetings at the Leerink Partners 2024 Global Biopharma Conference, which will be held in Miami, FL from March 11-13, 2024. About MindMed MindMed is a clinical stage biopharma.
- 03/11/2024
|
PLTR, MNMD, ODD: Finding Value in the Market
- Hilary Kramer discusses finding value in the market. She talks about her stock picks which include Palantir (PLTR), Mind Medicine (MNMD), Oddity (ODD), Prairie Operating (PROP), Starbucks (SBUX), and Arm Holdings (ARM).
- 03/08/2024
|
MindMed's (MNMD) Anxiety Drug Gets FDA Breakthrough Therapy Tag
- The FDA bestows a breakthrough therapy designation to MindMed's (MNMD) MM120 for treating generalized anxiety disorder. Shares rise more than 50% on the news.
- 03/08/2024
|
Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder
- VANCOUVER, BC , March 8, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based novel therapies, congratulates Mind Medicine ("MindMed" NASDAQ: MNMD, Cboe Canada: MMED) on the positive data generated from its Phase 2b clinical trial of MM120 (lysergide d-tartrate) for the treatment of generalized anxiety disorder ("GAD"). The study showed that four weeks after a single 100-microgram dose of MM120, 48 percent of the participants achieved remission and no longer showed clinically significant anxiety, and 65 percent showed clinically meaningful improvement.
- 03/08/2024
|
Psychedelics stocks fly as FDA recognizes Mind Medicine's LSD drug as breakthrough therapy
- Psychedelics stocks traded higher on Thursday as investor optimism returned to the sector on the news that MindMed (NASDAQ:MNMD, NEO:MMED)'s LSD drug candidate was granted breakthrough therapy status by the US Food and Drug Administration (FDA) for the treatment of generalized anxiety disorder (GAD). Shares of MindMed (NASDAQ:MNMD, NEO:MMED) led the charge, gaining 54% at US$9.15 in the mid-afternoon.
- 03/07/2024
|
Why Is MindMed (MNMD) Stock Up 32% Today?
- MindMed (NASDAQ: MNMD ) stock is on the rise Thursday after the clinical-stage biopharmaceutical company received breakthrough therapy designation from the Food and Drug Administration (FDA). This designation covers the company's MM120 program in development to treat generalized anxiety disorder.
- 03/07/2024
|
Mind Medicine's LSD drug candidate awarded FDA breakthrough therapy designation; shares soar
- MindMed (NASDAQ:MNMD, NEO:MMED) shares soared more than 26% higher before Thursday's opening bell after the biopharmaceutical firm revealed that its drug candidate MM120 has been awarded breakthrough therapy status from the US Food and Drug Administration (FDA) for the treatment of generalized anxiety disorder (GAD). MM120 is the tartrate sale form of lysergide (LSD) being developed by MindMed (NASDAQ:MNMD, NEO:MMED) for GAD and other potential applications in brain health disorders.
- 03/07/2024
|
Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement
- NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten offering of 16,666,667 common shares, no par value per share, at an offering price of $6.00 per common share. In addition, the Company has entered into share purchase agreements for a concurrent private placement of 12,.
- 03/07/2024
|
MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
- NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that FDA has granted breakthrough designation to its MM120 (lysergide d-tartrate) program for the treatment of generalized anxiety disorder (GAD). The Company also announced that its Phase 2b study of MM120 in GAD met its key secondary endpoint, and.
- 03/07/2024
|
MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120
- NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a conference call and webcast on March 7, 2024. The program will provide an update on MM120 in Generalized Anxiety Disorder (GAD), including 12-week topline safety, efficacy, and durability results from the Company's Phase 2b tria.
- 03/01/2024
|
Why Is MindMed (MNMD) Stock Up 8% Today?
- A positive news update for Mind Medicine (NASDAQ: MNMD ) is elevating the entire psychedelic treatment sector today. Specifically, the U.S. Food and Drug Administration (FDA) has just granted midomafetamine capsules (MDMA) a priority review.
- 02/12/2024
|
De-Risking Psychedelics: Compass Pathways, Cybin And Atai
- Critical catalysts are approaching in the psychedelic sector, with the potential for the first FDA-approved psychedelic therapy by the end of the year.
- 01/09/2024
|
What Makes Mind Medicine (MindMed) Inc. (MNMD) a New Buy Stock
- Mind Medicine (MindMed) Inc. (MNMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 12/20/2023
|
Mind Medicine's MM-120 shows promise in Phase 2b trial for Generalized Anxiety Disorder
- Mind Medicine (MindMed (NASDAQ:MNMD, NEO:MMED)) has announced encouraging results from its Phase 2b clinical trial of MM-120 in treating Generalized Anxiety Disorder (GAD). MM-120, a single-dose lysergide d-tartrate, demonstrated statistically significant and clinically meaningful improvements over placebo at Week 4, meeting its primary endpoint.
- 12/14/2023
|
MindMed announces positive results in trial of LSD as a treatment for generalized anxiety disorder
- Mind Medicine Inc. MNMD, +3.53% said Thursday a Phase 2 trial testing LSD as a treatment for generalized anxiety disorder met its main goal, showing a statistically significant improvement in scores by week four compared to placebo. The trial of MM-120 was administered as a single dose in a monitored clinical setting with no additional therapeutic intervention.
- 12/14/2023
|
Mind Medicine (MindMed) Inc. (MNMD) Q3 2023 Earnings Call Transcript
- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q3 2023 Results Conference Call November 2, 2023 4:30 PM ET Company Participants Rob Barrow - Chief Executive Officer Schond Greenway - Chief Financial Officer Dr. Dan Karlin - Chief Medical Officer Dr. Francois Lilienthal - Chief Commercial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Francois Brisebois - Oppenheimer Jonathan Aschoff - ROTH MKM Operator Good afternoon, and welcome to the Mind Medicine Third Quarter 2023 Financial Results and Corporate Update Conference Call. Currently, all participants are in listen-only mode.
- 11/02/2023
|
Mind Medicine: Q4 Of 2023 Data For GAD Makes This Worth A Look
- Results from the phase 2b study, using MM-120 for the treatment of patients with generalized anxiety disorder, expected Q4 of 2023. The Generalized Anxiety Disorder market is set to reach $7.4 billion in 2023. Results from phase 2a proof-of-concept study, using MM-120 for the treatment of patients with ADHD, expected Q4 2023 or Q1 of 2024.
- 10/13/2023
|
3 Pharma Stocks to Dump Before the Damage Is Done
- Pharma stocks and the biotech sector can offer explosive gains. It also offers incredibly crushing defeats in which share prices decline precipitously.
- 10/08/2023
|
MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress
- NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will present preclinical data for MM-402 in a model for autism spectrum disorder.
- 10/03/2023
|
MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Business Update
- NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will provide a corporate update and review the Company's results for the quarter ended June 30, 2023.
- 07/31/2023
|
The 3 Best Psychedelic Stocks to Buy Now
- Psychedelic stocks have a bright future with 13.5% compound annual growth expected through 2029. That growth will certainly draw in investment funding that seeks to capitalize on growth, as psychedelic drugs quickly become a hot topic in the mental health space.
- 06/29/2023
|
Psychedelic clinical trials: A glimpse at hotly-anticipated upcoming results
- As part of the renewed interest in the potential health applications of psychedelics in recent years, companies ranging from biotechnology startups to pharmaceutical giants are conducting ground-breaking clinical trials involving a range of psychedelic compounds including psilocybin, MDMA, and LSD. The results of these trials will likely create more innovative treatments for a range of physical and mental health conditions.
- 06/27/2023
|
TOMS Shoes founder is pledging $100 million for psychedelic research – Here's why he's doing it.
- Blake Mycoskie, founder of the canvas-footwear phenomenon TOMS Shoes, has committed to giving $100 million to support psychedelic research and access, Mycoskie told MarketWatch in an exclusive interview. The money will help fund academic institutions investigating psychedelics' potential to treat anxiety, depression, post-traumatic stress disorder and other mental-health issues, as well as nonprofits helping to connect patients in need with psychedelic treatments.
- 06/21/2023
|
Numinus Wellness designated as a top research site for MindMed study
- Numinus Wellness Inc. (TSX:NUMI, OTC:LKYSF) said it has been designated as a top research site for MindMed Inc's (NASDAQ:MNMD, NEO:MMED) Phase 2b study on MM-120 (lysergide D-tartrate) for General Anxiety Disorder. The company's Cedar Clinical Research (CCR), located in Draper, Utah, has emerged as the leading site for the study, having successfully enrolled and dosed 19 clinical trial participants thus far.
- 06/05/2023
|
MindMed to Participate at Upcoming Investor Conferences
- NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed announced today that members of the Company's management team will participate in several June investor conferences.
- 06/01/2023
|
MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting
- NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will present preclinical data of MM-402, the Company's proprietary form of R-MDMA, in a model for autism spectrum disorder.
- 05/24/2023
|
MindMed (MNMD) Up on 50% Enrollment in Anxiety Disorder Study
- MindMed's (MNMD) mid-stage study, evaluating MM-120 for treating general anxiety disorder, reaches over 50% enrollment mark. Its top-line data is expected in late 2023.
- 05/18/2023
|
MindMed a ‘Speculative Buy' ahead of key trial data readouts, broker says
- Analysts at Canaccord Genuity (TSX:CF, LSE:CF) have reiterated their ‘Speculative Buy' rating for MindMed (NASDAQ:MNMD, NEO:MMED) after the clinical-stage biotechnology company reaffirmed its budgets and clinical timelines with the release of its first quarter results. “As a clinical-stage biotechnology company, quarterly financials are not a materially impactful event,” the analysts wrote in a note to clients.
- 05/09/2023
|
3 High-Growth Penny Stocks to Consider Buying in April 2023
- The search for top penny stocks to buy in April, or in any month, is certainly an intriguing one. There are thousands of small and micro-cap stocks to choose from.
- 05/01/2023
|
MindMed stock jumps 4.5% after psychedelics company reports positive findings in trial of LSD as treatment for major depressive disorder
- The stock of psychedelics company Mind Medicine Inc. MNMD, +4.82% rose 4% Friday, after the company's Swiss research partners reported positive results from a Phase 2 trial of LSD as a treatment for major depressive disorder, or MDD. The trial involving 61 patients showed “rapid, durable and beneficial effects” of LSD in mitigating the symptoms of MDD, the company said in a statement.
- 04/14/2023
|
MindMed shares spike on positive results from LSD trial
- MindMed (NASDAQ:MNMD, NEO:MMED)'s shares moved higher after the biopharmaceutical company released positive topline data from its collaborators' trial evaluating lysergide (LSD) in the treatment of major depressive disorder (MDD). After spiking about 10% earlier in the day, MindMed (NASDAQ:MNMD, NEO:MMED) shares were trading up about 0.7% at US$3.12 shortly before 11am in New York.
- 04/14/2023
|
Why Is Mind Medicine (MNMD) Stock Up 26% Today?
- Mind Medicine (NASDAQ: MNMD ) stock is on the rise Friday after releasing positive results from a Phase 2 clinical trial. That clinical trial saw the company testing the effectiveness of treating MDD with LSD.
- 04/14/2023
|
The 7 Most Promising Psychedelic Stocks to Buy in February
- Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value.
- 02/05/2023
|
Psychedelic Sunday: Competitive Strategies
- Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage?
- 01/15/2023
|
Scrutinizing Psychedelic Stocks
- What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management.
- 01/08/2023
|
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
- Atai, Biogen, and Sage are working to develop new treatments for mental illness.
- 12/06/2022
|
MindMed price target lowered by Canaccord analysts after Phase 2a US clinical trial shelved
- Mind Medicine (MindMed (NASDAQ:MNMD, NEO:MMED)) Inc has earned a repeat ‘Speculative Buy' rating with a lowered price target of US$18 from US$22 per share from Canaccord Genuity (TSX:CF, LSE:CF) analysts following the release of its third-quarter results last week. The biotechnology company's shares are currently trading at about US$2.60 per share.
- 11/21/2022
|
Mind Medicine (MindMed), Inc. (MNMD) Q3 2022 Earnings Call Transcript
- Mind Medicine (MindMed), Inc. (NASDAQ:MNMD ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Robert Barrow - CEO & Director Schond Greenway - CFO Daniel Karlin - Chief Medical Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Elemer Piros - ROTH Capital Partners Patrick Trucchio - H.C. Wainwright & Co. Sepehr Manochehry - Eight Capital Operator Good day, and welcome to the Mind Medicine Third Quarter 2022 Financial Results and Corporate Update Conference Call.
- 11/10/2022
|
7 Speculative Penny Stocks Under $3 That Deserve Your Attention in Nov.
- Risk is part of investing. Even the most mature, well-established firms and stocks run the risk of declining to zero.
- 10/28/2022
|
Mind Medicine (MNMD) to Report Q3 Earnings: What's in Store?
- Mind Medicine MindMed (MNMD) is expected to provide an update on its pipeline candidates in its third-quarter earnings.
- 10/26/2022
|
10 Top Penny Stocks To Buy According To Wall Street Analysts In 2022
- Penny stocks to buy according to analysts in 2022. The post 10 Top Penny Stocks To Buy According To Wall Street Analysts In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/19/2022
|
Why Mind Medicine Zoomed 8% Higher on Tuesday
- The support for legalizing drugs -- such as those being studied by the company -- grows with a U.S. senator's tweet.
- 10/18/2022
|
7 Penny Stocks To Buy According To Top Wall Street Analysts
- Penny stocks to buy according to analysts in 2022. The post 7 Penny Stocks To Buy According To Top Wall Street Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/18/2022
|
These Were The Five Best And Worst Performing Healthcare Stocks In September 2022
- September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.
- 10/17/2022
|
Why Mind Medicine Stock Triumphed on Tuesday
- The company is going back into the lab, and investors are eager to see what it discovers.
- 10/04/2022
|
Why Mind Medicine Stock Soared on a Down Day for the Market
- A highly dilutive new round of financing is making the stock behave like a yo-yo.
- 09/29/2022
|
Best Penny Stocks To Buy Now? 3 To Watch As Stock Market Crash Continues
- Biotech penny stocks to watch as stock market crash continues today. The post Best Penny Stocks To Buy Now?
- 09/29/2022
|
Stock of psychedelics company MindMed slides 50% after it sells fresh shares
- Shares of psychedelics company Mind Medicine Inc. slid 50% Wednesday, after the company priced a dilutive secondary offering of 7.1 million shares.
- 09/28/2022
|
Why Mind Medicine (MindMed) Stock Is Crashing Today
- The maker of psychedelic drugs announced the pricing of its latest public offering.
- 09/28/2022
|
Why Is MindMed (MNMD) Stock Plunging 51% Today?
- MindMed (NASDAQ: MNMD ) stock is plunging 51% today after the drug maker announced yesterday shortly before the market closed that it would sell an undisclosed number of common shares of MMED stock, along with an undisclosed number of warrants. The company did not indicate the price at which the securities would be sold.
- 09/28/2022
|
Psychedelics company MindMed's shares slide 36% premarket as it prices dilutive 7.1 million share secondary offering
- Shares of psychedelics company Mind Medicine Inc. MNMD, +6.43% slid 35.6% in premarket trade Wednesday, after the company priced a dilutive secondary offering of 7.1 million shares. The offering priced at $4.25 a share, below the stock's closing price Tuesday of $6.12.
- 09/28/2022
|
Stocks moving after hours: Big Bank stocks, Meta, MindMed
- Yahoo Finance's Seana Smith breaks down major stock moves after the closing bell.
- 09/27/2022
|
Wall Street Says This Stock Can Deliver a 543% Return. Should You Listen?
- Find out why investment bank analysts think this stock is positioned for a six-fold gain.
- 09/15/2022
|
MindMed (MNMD) Stock Regains Nasdaq Compliance
- Source: Daniel Patrick Martin / Shutterstock.com MindMed (NASDAQ: MNMD ) stock is in the news Wednesday after the psychedelic medicine company regained Nasdaq compliance. According to a press release from the company, it has satisfied the Nasdaq's minimum bid price listing requirement.
- 09/14/2022
|
Why Mind Medicine (MindMed) Stock Tumbled This Week
- MindMed's stock has been moving lower ever since its reverse split last month.
- 09/08/2022
|
MindMed (MNMD) Stock Is Up on Psychedelics News
- Source: Daniel Patrick Martin / Shutterstock.com MindMed (NASDAQ: MNMD ) stock is on the move Wednesday following positive data from a Phase II clinical trial of MM-120. MM-120 is an LSD treatment in development for patients suffering from anxiety disorders.
- 09/08/2022
|
This Meme Stock Just Did a Huge Reverse Stock Split
- Is Mind Medicine a buy?
- 09/08/2022
|
Mind Medicine shares up as Phase 2b studies continue on medical LSD
- Mind Medicine Inc. MNMD, -7.06% (MindMed) shares rose 10% in premarket trades on Thursday after the company said patient dosing in its Phase 2b trial is ongoing and offers a "highly attractive commercial opportunity." The clinical stage biopharmaceutical company that's developing psychedelic medicine to treat brain health disorders said a manuscript that expands on previously reported positive data has been published in the peer-reviewed scientific journal, Biological Psychiatry.
- 09/08/2022
|
5 Top Stocks to Buy on New Analysts' Coverage
- Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Napco Security (NSSC), Proto Labs (PRLB), Clear Secure (YOU), AVEO and Mind Medicine (MNMD).
- 09/06/2022
|
After Its Reverse Stock Split, Is Mind Medicine a Buy?
- If you can stomach the risks, the reverse split doesn't change much of anything.
- 09/05/2022
|
3 Reasons Why Mind Medicine Might Be the Next Monster Meme Stock
- It already has many of the ingredients for memehood.
- 09/02/2022
|
7 Psychedelics Stocks to Buy for a Big Drug Boom
- Psychedelics stocks are becoming increasingly mainstream, in part due to changing social attitudes. Psychedelic drugs “are a loosely grouped class of drugs that are able to induce altered thoughts and sensory perceptions.
- 08/30/2022
|
Europe is in Crisis
- European energy costs are 10X the norm
- 08/29/2022
|
MindMed (MNMD) Stock Falls After Reverse Stock Split
- Mind Medicine (NASDAQ: MNMD ) stock, which had been rising on small trader interest and positive updates, fell nearly 10% as it enacted a 1-for-15 reverse stock split. The stock was also helped by rumors of a short squeeze Aug. 18, which sent it to a post-split high of $19.95 per share.
- 08/29/2022
|
Mind Medicine (MindMed) (MNMD) Stock: 1-For-15 Split Goes Into Effect
- A 1-for-15 split of Mind Medicine (MindMed) Inc (MNMD) has gone into effect. These are the details.
- 08/29/2022
|
Dear MNMD Stock Fans, Watch This Key Catalyst
- Psychedelics have been in the national spotlight recently and MindMed (NASDAQ: MNMD ) stock has been enjoying the ride. Its mission is to address patient needs through “the therapeutic potential of psychedelics and other novel compounds.
- 08/26/2022
|
Mind Medicine ($MNMD) Doses First Patient in Phase 2b Trial to Treat Generalized Anxiety Disorder
- Mind Medicine ($MNMD) a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, has announced first patient dosing in its Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid diethylamide for the treatment of Generalized Anxiety Disorder. The Phase 2b trial in patients diagnosed with GAD is a multi-center, parallel, randomized, double-blind, placebo-controlled, dose-optimization study.
- 08/25/2022
|
Why Shares of Mind Medicine Rose 12.9% on Monday
- The company could become a meme stock, which is drawing interest.
- 08/22/2022
|
Don't Get Squeezed Out of Your Money with Mind Medicine Stock
- New York-headquartered Mind Medicine (NASDAQ: MNMD ), sometimes informally known as MindMed, was largely unknown on Wall Street. Recently, however, Mind Medicine garnered attention because one meme-stock trader reportedly bought shares of MNMD stock.
- 08/22/2022
|
3 Growth Stocks That Could Soar 51% to 385%, According to Wall Street
- Expectations for these stocks are still sky high.
- 08/22/2022
|
Bed, Bath (BBBY) Shareholders Buffeted by Large Meme Player Sales, MindMed (MNMD) Now in Their Sight
- Jake Freeman might be the first meme activist. The 20-year-old New Jersey student, with help from friends and family, burst onto the scene after the Financial Times profiled him and his group's 6.2% Bed, Bath and Beyond (US:BBBY) stake that's earned them $110 million in the company's recent run-up.
- 08/19/2022
|
The Hidden Reason MindMed (MNMD) Stock Is Still Climbing
- Source: Daniel Patrick Martin / Shutterstock.com MindMed (NASDAQ: MNMD ) stock is a hot topic on Friday as the company's shares continue to rally higher with investors seeing it as a short-squeeze target. But that's not the only reason shares of MNMD are on the move today.
- 08/19/2022
|
Hot Penny Stocks to Add to Your Watchlist Right Now
- Here's what you need to know about buying penny stocks on August 19th The post Hot Penny Stocks to Add to Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/19/2022
|
Get Ready for “Up, Up, and Away”
- Why Louis Navellier sees no more hikes after September
- 08/18/2022
|
Why Mind Medicine (MindMed) Stock Is Crushing It Today
- Investors appear to think that MindMed could deliver huge gains the way Bed Bath & Beyond has in recent weeks.
- 08/18/2022
|
Is MindMed (MNMD) Stock the Next Big Short Squeeze?
- Penny stock Mind Medicine (NASDAQ: MNMD ) stock nearly doubled overnight on rumors of a short squeeze. Shares that opened at 68 cents early on Aug. 17 were trading at $1.16 before the market opened on Aug. 18, after trading as high as $1.40 earlier in the morning.
- 08/18/2022
|
Penny Stocks To Buy? 3 Under $0.99 For Your Watch List
- Penny stocks under $1 to watch this week. The post Penny Stocks To Buy?
- 08/17/2022
|
Why Mind Medicine Stock Crushed the Market on Friday
- Investors trade up the psychedelics-focused biotech's shares after an eventful day.
- 08/12/2022
|
5 Penny Stocks To Buy For Under $5
- Hot penny stocks to watch or buy for under $5? Here's a list of .penny stocks gaining momentum today The post 5 Penny Stocks To Buy For Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/12/2022
|
Mind Medicine (MindMed) Inc. (MNMD) CEO Robert Barrow on Q2 2022 Results - Earnings Call Transcript
- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q2 2022 Results Conference Call August 11, 2022 4:30 PM ET Company Participants Robert Barrow - Chief Executive Officer Schond Greenway - Chief Financial Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Elemer Piros - ROTH Capital Partners Patrick Trucchio - H.C. Wainwright Sepehr Manochehry - Eight Capital Operator Good afternoon and welcome to the Mind Medicine Second Quarter 2022 Financial Results and Corporate Update Conference Call.
- 08/11/2022
|
3 Best Psychedelic Stocks to Buy Now
- The incredible healing properties of psychedelics are being discovered with every passing day. Their potential is massive and can flip the script for those struggling with mental health disorders.
- 08/09/2022
|
The Growth Potential Of Psychedelics Stocks And ETFs
- On July 13, 2022, two amendments passed in the House of Representatives that would provide psychedelic drug treatment to veterans and active duty service members. A documentary based on Michael Pollan's 2018 book, "How to Change Your Mind," is one of Netflix's most-watched shows.
- 07/28/2022
|
Penny Stocks To Buy Today? 3 To Watch With Price Targets Up To 1,152%
- Penny stocks to buy according to analysts The post Penny Stocks To Buy Today? 3 To Watch With Price Targets Up To 1,152% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/27/2022
|
Mind Medicine(MNMD) CEO Rob Barrow on Q1 2022 Results - Earnings Call Transcript
- Mind Medicine(NASDAQ:MNMD ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Rob Barrow - CEO Dan Karlin - Chief Medical Officer Miri Halperin Wernli - Executive President Conference Call Participants Patrick Trucchio - H.C. Wainwright Michael Okunewitch - Maxim Elemer Piros - ROTH Capital Sepehr Manochehry - Eight Capital Tania Armstrong-Whitworth - Canaccord Genuity Operator Good morning and welcome to the Mind Medicine First Quarter 2022 Financial Results and Corporate Update Conference Call.
- 05/16/2022
|
Penny Stocks With Huge Potential According To 4 Wall Street Analysts
- Penny stocks with huge potential according to analysts in 2022. The post Penny Stocks With Huge Potential According To 4 Wall Street Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/04/2022
|
Interested in Investing in Psychedelics? Check Out This Podcast.
- And other market news.
- 04/19/2022
|
MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium
- - "LSD as a Treatment for Anxiety Disorders: New Evidence of Efficacy" will present the most recent and robust data on LSD in patients with anxiety - - This study builds on decades of research on the effects of LSD in humans - NEW YORK , April 14, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that Dr. Frederike Holze and Prof. Dr. Matthias Liechti, MindMed collaborators at University Hospital Basel (UHB), will present results from the LSD-Assist Study, a Phase 2 investigator-initiated clinical trial of LSD in the treatment of anxiety disorders, at London's PSYCH Symposium on May 11, 2022.
- 04/14/2022
|
MindMed CEO: Psychedelic medicine industry is a 'massive opportunity'
- MindMed CEO Rob Barrow sits down with Yahoo Finance Live to talk about rising interests in the psychedelic medicine industry, therapeutic uses for addressing and treating anxiety, and removing mental health stigmas.
- 04/09/2022
|
Mind Medicine (MindMed) Inc. (MNMD) CEO Rob Barrow on Q4 2021 Results - Earnings Call Transcript
- Mind Medicine (MindMed) Inc. (MNMD) CEO Rob Barrow on Q4 2021 Results - Earnings Call Transcript
- 03/28/2022
|
America faces a serious mental health crisis, this is how MindMed aims to fix this
- (Kitco News) - America faces a serious mental health crisis, this is how MindMed aims to fix this
- 02/18/2022
|
Cybin, MindMed, and Field Trip Health Headline PSYC's First CEO Round Table Event
- Media company Global Trac Solutions, Inc. (OTCP:PSYC) and authorities behind psychedelic news and information platform Psychedelic Spotlight, announced that Psychedelic Spotlight will host its first “CEO Roundtable” on Feb. 15. The event is scheduled to be streamed live on YouTube via The Psychedelic Investor channel, and will be moderated by James Hallifax, journalist and content director for Psychedelic Spotlight.
- 02/14/2022
|
Why Shares of Mind Medicine Jumped 13.4% on Wednesday
- The clinical-stage biopharmaceutical company benefited from an increased interest in companies working on psychedelic therapies.
- 02/09/2022
|
FDA Greenlight Sets the Stage for Upside With Mind Medicine
- Few catalysts can move healthcare stocks like a regulatory clearance can - and MNMD stock could be 2022's top psychedelics-sector investment. The post FDA Greenlight Sets the Stage for Upside With Mind Medicine appeared first on InvestorPlace.
- 02/08/2022
|
5 Penny Stocks To Buy Right Now According To Reddit Social Sentiment
- Reddit penny stocks to watch in February. The post 5 Penny Stocks To Buy Right Now According To Reddit Social Sentiment appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 02/04/2022
|
5 Top Penny Stocks To Buy Under $5 Right Now
- Penny stocks to buy for under $5. The post 5 Top Penny Stocks To Buy Under $5 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/28/2022
|
MindMed: Falling Uncontrollably
- The recent decline in MindMed's share price is a result of changes to the broader macroeconomic landscape.
- 01/27/2022
|
MindMed Shares Soar After FDA Approves First Commercial Clinical Trial On LSD In 40 Years
- MindMed (NASDAQ:MNMD), a drug development company in the psychedelics space, announced on Tuesday that the FDA has allowed an investigational new drug application for a Phase 2b trial on a proprietary LSD analog. Shares from the company peaked at $1.30 and closed the Tuesday trading session at $1.17, marking a 25% increase from the previous day.
- 01/26/2022
|
Mind Medicine, Mindset Pharma Among Top Psychedelic Movers Of Today
- Mind Medicine (NASDAQ:MNMD) shares closed up 25.48% at $1.17 Mindset Pharma (OTC:MSSTF) shares closed up 15.85% at $0.47
- 01/25/2022
|
MNMD Stock: The FDA Go-Ahead That Has MindMed Investors Feeling Euphoric Today
- MindMed (MNMD) stock is getting a buzz today thanks to approval from the FDA to move forward with a clinical trial of MM-120. The post MNMD Stock: The FDA Go-Ahead That Has MindMed Investors Feeling Euphoric Today appeared first on InvestorPlace.
- 01/25/2022
|
MindMed Successfully Completes Phase 1 Trial Of 18-MC
- This article was originally published on Microdose and appears here with permission. MindMed ended its 2021 news cycle on a somewhat mehhh note.
- 01/19/2022
|
MindMed Launches Study Using Monitoring System For Psychedelic Experiences
- Psychedelics biotech company MindMed (NASDAQ:MNMD) has enrolled the first subjects into its Session Monitoring System study. The company's Session Monitoring System is a technology platform that can collect sensory data during a therapy session with a psychedelic drug.
- 01/18/2022
|
MindMed Completes Phase 1 Clinical Trial Of Non-Hallucinogenic Proprietary Derivative Of Ibogaine
- On Tuesday, Mind Medicine Inc. (NASDAQ:MNMD) (NEO: MMED) (DE: MMQ) reported the completion of its Phase 1 clinical trial of 18-MC, the company's non-hallucinogenic proprietary derivative of ibogaine, being developed for the treatment of indications linked to opioid use disorder. The New York-headquartered psychedelic-focused biotech company noted that the trial was completed in December 2021 with topline results expected in early 2022.
- 01/04/2022
|
MindMed Shares Update On Phase 2b Trials of LSD For Treating Generalized Anxiety Disorder
- MindMed (NASDAQ: MNMD) (NEO: MMED), a clinical-stage biotech company that is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, announced on Dec. 21 that the Food and Drug Administration (FDA) has placed a clinical hold on its IND submission intended to support the initiation of a Phase 2b trial of lysergic acid diethylamide (LSD) for the treatment of generalized anxiety disorder (GAD). Additional detail regarding the FDA's decision is expected within 30 days.
- 12/22/2021
|
MNMD Stock: The Latest Psychedelic Drug News MindMed Fans Should Watch
- MindMed's LSD trials are facing a regulatory roadblock but MNMD stock isn't being forced down. Here's why investors should watch.
- 12/21/2021
|
MindMed Advances Phase 2a LSD Microdose Trial For Adult ADHD
- Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced Friday the initiation of Phase 2a proof-of-concept trial of LSD (lysergic acid diethylamide) in adult patients with attention deficit hyperactivity disorder. The company said it expects to start patient enrollment soon, considering that the first site has been activated.
- 12/17/2021
|
MindMed Names Robert Barrow As CEO & Director, Announces Management Shake-Ups
- Psychedelic-focused biotech company Mind Medicine Inc. (NASDAQ:MNMD) (NEO: MMED) (DE: MMQ) announced Tuesday that Robert Barrow has been appointed CEO and member of the board of directors. Barrow, an accomplished pharmaceutical executive and a recognized leader in the psychedelic industry, is bringing over a decade of experience leading organizations and drug development programs to the New York-based company.
- 12/14/2021
|
Mind Medicine Stock (MNMD): Why The Price Increased Today
- The stock price of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) increased by over 2% pre-market today. This is why it happened.
- 12/14/2021
|
FDA Shows Support For Development Of MindMed's Session Monitoring System
- Psychedelic-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) recently met with the US Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) with consultation from the Center for Drug Evaluation and Research (CDER) to discuss several key points for ongoing development of the MindMed Session Monitoring System. During a device pre-submission meeting, which was held on October 25, MindMed presented the FDA with a working Indications for Use statement (IFU) and a development roadmap.
- 12/09/2021
|
9 Psychedelic Stocks to Watch For 2022
- The usage of psychedelics like psilocybin, LSD, ketamine, and others are becoming more mainstream, especially with the initial steps to legalization getting moving across a number of states in the U.S. As a result, the psychedelics market is projected to grow 12.4% annually, reaching $10.75 billion in 2027.
- 12/06/2021
|
MindMed to Present at H.C. Wainwright 2nd Annual Psychedelics Conference
- NEW YORK, Dec. 1, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that MindMed's Chief Executive Officer, Robert Barrow, will participate in a panel and Company's management will participate in one-on-one investor meetings at the virtual H.C. Wainwright 2nd Annual Psychedelics Conference to be held on Monday, December 6, 2021.
- 12/01/2021
|
Antidepressants Can Be Used During Psilocybin Treatment, A New MindMed & Liechti Lab Study Finds
- Psychedelics-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced the publication of its first data on the interaction of a selective serotonin uptake inhibitor, known as escitalopram, with an acute response to psilocybin in humans. The publication is based on a randomized, double-blind, placebo-controlled, crossover pharmacology study in healthy volunteers and was published in Clinical Pharmacology and Therapeutics.
- 11/30/2021
|
3 Psychedelic Stocks for Potential Out-of-This-World Gains
- Psychedelic drugs could be a major game-changer when it comes to treating mental illness. All as psilocybin, LSD, and MDMA show progress.
- 11/18/2021
|
MindMed Q3 Earnings: Big Improvement, Kicks Off Sleep & Cognitive Study With Dose Low-Dose LSD
- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a biotech company developing psychedelic-inspired therapies, announced its financial results late Monday for the third quarter ended Sept. 30, 2021. Q3 & Nine Months 2021 Financial Highlights Total assets were $178.6 million, including $145.9 million in cash, as compared to $85.6 million, including $80.1 million in cash, as of Dec. 31, 2020.
- 11/16/2021
|
MindMed to Present at the Jefferies London Healthcare Conference
- NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its CEO, Robert Barrow, will be speaking at Jefferies 2021 London Healthcare Conference, taking place on November 16-19. Management will be available during the conference for in-person and virtual one-on-one meetings.
- 11/12/2021
|
Behind the Wall: Psychedelics Have “Absolutely Transformational” Potential
- Is now the time to invest in psychedelic stocks? Dustin Robinson, founder of venture capital firm Iter Investments, says yes and explains why.
- 11/11/2021
|
MindMed to Present at Web Summit on Future of Mental Health
- NEW YORK, Nov. 1, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that CEO Robert Barrow will be speaking at Web Summit , taking place on November 1-4, 2021 in Lisbon, Portugal. Barrow will be interviewed at 11:45am WET on November 3 on the topic, " Therapy 2.0 - The next step in mental health ".
- 11/01/2021
|
7 Penny Stocks to Buy – While They're Still Penny Stocks
- So, which penny stocks should you buy, with the potential to break through the ceiling, en route to higher prices? Consider these seven top names that could do just that: Cinedigm (NASDAQ:CIDM) Vaalco Energy (NYSE:EGY) Globalstar (NYSEAMERICAN:GSAT) Mind Medicine (NASDAQ:MNMD) Romeo Power (NYSE:RMO) Senseonics (NYSEAMERICAN:SENS) Uranium Energy (NYSEAMERICAN:UEC) The post 7 Penny Stocks to Buy – While They're Still Penny Stocks appeared first on InvestorPlace.
- 10/19/2021
|
3 Penny Stocks Waiting on FDA Approval for Rocket Fuel
- Several penny stocks out there have done very well recently but these three biotechs are waiting for positive FDA news to soar higher. The post 3 Penny Stocks Waiting on FDA Approval for Rocket Fuel appeared first on InvestorPlace.
- 10/18/2021
|
MindMed Joins Clinical Trials Transformation Initiative
- NEW YORK, Oct. 13, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has joined the Clinical Trials Transformation Initiative (CTTI) to contribute in developing and driving adoption of practices that increase the quality and efficiency of clinical trials. MindMed joins CTTI as one of approximately 80 member organizations interested in advancing higher quality clinical trials and accelerating the path to new therapeutics and other medical products.
- 10/13/2021
|
7 Penny Stocks to Pick Up if You Have $100 to Spare
- They're not exactly names you want to bet the ranch on. Still, a $100 position in each of these penny stocks could be worth the risk.
- 10/07/2021
|
MindMed Teams Up With Sphere Health To Identify Biomarkers Associated With Anxiety & Depression
- Psychedelic–focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) disclosed on Tuesday that it has agreed to partner with Sphere Health to collect and analyze multimodal data in order to improve the understanding of a variety of biomarkers associated with certain mental illnesses. Under the strategic research collaboration, Sphere Health - a physician-founded employee benefits provider targeting treatments for people with severe mental illness – and MindMed are launching MM061302 in an attempt to develop more accurate machine learning tools to identify biomarkers that show association with and prediction of symptoms of anxiety and affective disorders.
- 10/05/2021
|
MindMed Announces Strategic Research Collaboration with Sphere Health
- NEW YORK, Oct. 5, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has agreed to partner with Sphe re Health – a physician-founded employee benefits provider targeting treatments for people with severe mental illness – to collect and analyze multimodal data in order to improve the understanding of a variety of biomarkers associated with mental illnesses including anxiety and affective disorders. MindMed and Sphere Health are jointly launching MM061302, a study using existing consumer technology to provide a robust data set, which may be used to develop more accurate machine learning tools in order to identify biomarkers that show association with and prediction of symptoms of anxiety and depression.
- 10/05/2021
|
Psychedelic Front Runners MindMed , BioXcel Patent System To Identify Agitation
- This article by Gaurav Dubey was originally published on Microdose Psychedelic Insights and appears here with permission. The psychedelic front-runners at MindMed (NASDAQ:MNMD) have announced their partnership with BioXcel Therapeutics and published an International Patent Application describing a system for identifying agitation episodes.
- 10/04/2021
|
MindMed Announces Appointment of Andreas Krebs and Carol Vallone as Directors and Transition of Bruce Linton
- NEW YORK, Sept. 30, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) ("MindMed" or the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its board of directors has appointed Mr.
- 09/30/2021
|
MindMed Appoints University of North Carolina Psychiatrist and Pharmacologist Dr. Bryan Roth to Scientific Advisory Board
- NEW YORK, Sept. 29, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the addition of Bryan L.
- 09/29/2021
|
MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration
- NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Dr. Matthias Liechti presented data from several ongoing studies at the INSIGHT Conference in Berlin, Germany.
- 09/23/2021
|
7 of the Best Penny Stocks to Buy Coming Into Year-End
- These penny stocks are undervalued based on their fundamentals and have the potential to break through in the coming months. The post 7 of the Best Penny Stocks to Buy Coming Into Year-End appeared first on InvestorPlace.
- 09/21/2021
|
MindMed Announces Participation at Upcoming Investor Conferences
- NEW YORK, Sept. 21, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announces that Robert Barrow, Chief Executive Officer of MindMed, will participate in the following investor conferences: Advances in Mental Health Virtual Conference , presented by Maxim Group LLC and hosted by M-Vest Live Sessions Date: Wednesday, Sept.
- 09/21/2021
|
MindMed to Present at H.C. Wainwright 23rd Annual Global Investment Conference
- NEW YORK, Sept. 10, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Robert Barrow, Chief Executive Officer of MindMed, will present at the virtual H.C.
- 09/10/2021
|
7 Penny Stocks Waiting on The FDA for Rocket Fuel
- News of regulatory approval or progress would really help to move the needle for these seven biotech penny stocks. The post 7 Penny Stocks Waiting on The FDA for Rocket Fuel appeared first on InvestorPlace.
- 09/09/2021
|
MindMed to Attend 8th Annual "Mobile in Clinical Trials" Conference
- NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its Chief Medical Officer, Daniel R.
- 09/09/2021
|
Time to Buy the Magic Stocks? Magic Mushrooms, That Is.
- The first state to legalize cannabis for medical use was California, in 1996. In 2001, medical marijuana was approved in Canada.
- 09/08/2021
|
MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes
- NEW YORK, Sept. 2, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, and BioXcel Therapeutics, Inc. ("BioXcel"), a leading clinical-stage biopharmaceutical company, announce the publication of BioXcel's International Patent Application No.
- 09/02/2021
|
Mind Medicine: Short-Term Catalysts Fall Flat
- Inclusion in the MSCI and FTSE Indices led to short-term gains that quickly evaporated.
- 08/23/2021
|
MindMed: A Compelling Long-Term Buy In Biotech
- The acceptance of psychedelic treatments has been expedited over the past couple years, leaving companies like MindMed in great early positions to succeed. Normally, I would stay away from investing in biotech stocks; however, MindMed has the potential to revolutionize the healthcare industry, and I want to be a part of it.
- 08/22/2021
|
MindMed Joins Critical Path Institute's Patient-Reported Outcome Consortium
- NEW YORK, Aug. 17, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has joined the Critical Path Institute's ("C-Path's") Patient-Reported Outcome (PRO) Consortium to assist in the development of new approaches to advance medical innovation and regulatory science. C-Path ( www.c-path.org ) has multiple active consortia and programs that leverage knowledge sharing to spur innovation.
- 08/17/2021
|
Mind Medicine (MindMed) Inc. (MNMD) CEO Robert Barrow on Q2 2021 Results - Earnings Call Transcript
- Mind Medicine (MindMed) Inc. (MNMD) CEO Robert Barrow on Q2 2021 Results - Earnings Call Transcript
- 08/16/2021
|
Push the Boundaries of DMT Therapy with Mind Medicine
- Ready to explore an under-developed area of psychedelic medicine? If so, then consider a long position in low-priced MNMD stock.
- 08/16/2021
|
MindMed Reports Q2 Earnings With Net Loss of $36M And Cash Balance Of $157M To Continue With Its Clinical Pipeline
- The psychedelics-focused medicines company MindMed (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ), announced its second-quarter financial results Friday with a net and comprehensive loss of $36 million, which compares to a loss of $14 million in the previous quarter. Net cash used in operating activities during the quarter amounted to $12 million, versus a total cash burn of $10 million in the quarter ended March 31.
- 08/16/2021
|
MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD Million ($195 CAD Million) to Execute on Diverse Clinical Pipeline
- NEW YORK, Aug. 12, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD), (NEO: MMED), (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended June 30, 2021. Q2 2021 Financial Highlights (in USD) Total assets as of June 30, 2021 were $194 million, including $157 million in cash Net Cash Used in Operating Activities of $12 million for the quarter ended June 30, 2021 Net and comprehensive loss of $36 million for the quarter ended June 30, 2021 Q2 2021 Business Highlights MindMed launched Project Angie, targeting the treatment of pain with psychedelics MindMed launched a collaboration with Nextage Therapeutics to explore applications of psychedelics in a brain targeting liposome delivery system MindMed and the Liechti Lab published the first pharmacogenetic data on LSD MindMed appointed Dr. Sarah Vinson to its Board of Directors MindMed appointed Drs.
- 08/12/2021
|
10 Penny Stocks to Buy to Create a $500 Portfolio
- These ten low-priced penny stocks have ample room to gain, making them each worthy of a small, speculative investment. The post 10 Penny Stocks to Buy to Create a $500 Portfolio appeared first on InvestorPlace.
- 08/11/2021
|
No Matter How the Pandemic Rolls, Mind Medicine Will Prevail
- While MNMD stock is controversial due to its underlying psychedelic therapies, the broader narrative is exceptionally compelling. The post No Matter How the Pandemic Rolls, Mind Medicine Will Prevail appeared first on InvestorPlace.
- 08/11/2021
|
MindMed Appoints Dr. Robert Dworkin to Scientific Advisory Board
- NEW YORK, Aug. 10, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, announces the addition of Robert H. Dworkin, Ph.D.
- 08/10/2021
|
7 Stocks to Buy if You Think Alternative Therapies Are the Future
- Here are seven stocks to buy if you're optimistic about the potential for alternative therapies to become mainstream treatments. The post 7 Stocks to Buy if You Think Alternative Therapies Are the Future appeared first on InvestorPlace.
- 08/02/2021
|
MindMed Interim CEO on the growing competition in psychedelics industry
- This segment originally aired on July 29, 2021. Robert Barrow, MindMed Interim CEO, joins Yahoo Finance to discuss then transition in MindMed's CEO, future outlook for the company and the psychedelics industry.
- 08/01/2021
|
MindMed Leverages Ayahuasca's Ingredient DMT In Psychedelic-Inspired Therapies, Launches Trials With 30 Subjects
- Psychoactive brew ayahuasca is known for having a fast-onset antidepressant effect. With serotonergic psychedelics, such as ayahuasca, giving promising results in the quest for alternative treatments for depression and anxiety, many companies are turning their focus to developing psychedelic-inspired therapies.
- 07/29/2021
|
Mind Medicine Has More Obstacles Than Opportunities
- MNMD stock could revolutionize mental healthcare with its novel therapeutics, but there are currently too many risks with its business. The post Mind Medicine Has More Obstacles Than Opportunities appeared first on InvestorPlace.
- 07/20/2021
|
7 Top-Rated Pharmaceutical Companies to Invest In for July
- Pharma stocks like MNMD stock and ANVS stock offer investors long-term growth potential in a market on track to hit a value of $1.70 trillion. The post 7 Top-Rated Pharmaceutical Companies to Invest In for July appeared first on InvestorPlace.
- 07/09/2021
|
MindMed Stock Is Overvalued and Too Risky to Own
- MindMed can be the future of psychedelic medicines, but without cash flow from revenue, MNMD stock is nothing to get excited about. The post MindMed Stock Is Overvalued and Too Risky to Own appeared first on InvestorPlace.
- 07/08/2021
|
MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company
- NEW YORK, July 8, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, and Datavant, Inc. ("Datavant"), a leader in helping healthcare organizations safely connect their data, announced a partnership through which MindMed will use Datavant's privacy-protecting technology to link MindMed's clinical trial data to external data from both clinical and real-world sources. MindMed plans to use Datavant's linking technology across various stages of the drug lifecycle including discovery, clinical development, and commercialization.
- 07/08/2021
|
The MindMed Psychedelic Revolution Will Take Years to Come to Fruition
- MNMD stock aspires to be a lot to many but could flop. Prices are low, risk is high and speculators could become savants.
- 07/02/2021
|
Psychedelics-Focused MindMed Joins FTSE Russell 3000 Index, 'A True Honor'
- A psychedelics-focused medicine company MindMed (NASDAQ: MNMD) reported Monday that has been added to the FTSE Russell 3000 index, effective June 25th. The FTSE Russell 3000 index measures the performance of the 3,000 largest companies in the United States.
- 06/29/2021
|
MindMed Can Play a Big Role in the Growing Mental Wellness Industry
- MNMD stock is positioned for long-term growth as its LSD, MDMA, and Psilocybin-based treatments have a huge addressable mental wellness market. The post MindMed Can Play a Big Role in the Growing Mental Wellness Industry appeared first on InvestorPlace.
- 06/28/2021
|
Why This MindMed Analyst Is Bullish: 'One Of The Most Diverse Pipelines In Psychedelics'
- Mind Medicine (MindMed) Inc (NASDAQ:MNMD) shares traded higher by 3.3% on Monday after one analyst initiated bullish coverage of the psychedelics stock. The Analyst: Maxim analyst Jason McCarthy initiated coverage of MindMed with a Buy rating and $6 price target.
- 06/28/2021
|
MindMed Included in FTSE Russell 3000® Index
- NEW YORK, June 28, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic-inspired medicine company announced that effective Friday, June 25th, 2021, MindMed has been added to the FTSE Russell 3000® index which measures the performance of the largest 3,000 US companies. The annual Russell indexes reconstitution process captures the 4,000 largest US stocks in May of every year, ranking them by total market capitalization.
- 06/28/2021
|
7 Best Penny Stocks to Buy Now for Potential 10X Gains
- Penny stocks offer a lot of risk balanced by lots of reward. Here are 7 that could surge in price and which have reasonable catalysts behind them.
- 06/24/2021
|
MindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board
- NEW YORK, June 23, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Maurizio Fava, a world-leading expert in psychiatry and psychiatric clinical trials from Massachusetts General Hospital and the Harvard Medical School to the Company's Scientific Advisory Board. Dr. Fava obtained his MD from the University of Padova School of Medicine where he completed residency training in endocrinology.
- 06/23/2021
|
MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board
- NEW YORK, June 17, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Peter Bergethon, a world-leading expert in neurology, digital medicine, and central nervous system (CNS) drug development to the Company's Scientific Advisory Board. Dr. Bergethon is the Vice President and Head of Digital and Quantitative Medicine at Biogen Inc., where he leads the effort to transform clinical trials and humanize drug discovery by encouraging the transition of clinical trial measures from a qualitative to a quantitative discipline.
- 06/17/2021
|
Is Mind Medicine a Buy?
- It offers a great way to tap into the psychedelics market -- but is it too risky of an investment right now?
- 06/17/2021
|
4 Penny Stocks to Watch Following the Fed Meeting and Powell's Remarks
- Which penny stocks are investors watching following Powell's remarks and the Fed meeting? The post 4 Penny Stocks to Watch Following the Fed Meeting and Powell's Remarks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/16/2021
|
Could Mind Medicine Be a Millionaire-Maker Stock?
- Yes, but with the chance of great reward comes substantial risk.
- 06/16/2021
|
MNMD Stock Price Increases Over 3% Pre-Market: Why It Happened
- The stock price of Mind Medicine (MindMed) Inc (NASDAQ: MNMD) increased by over 3% pre-market. This is why it happened.
- 06/16/2021
|
3 Psychedelics Stocks Getting High Thanks to the Newly Launched PSY ETF
- These psychedelic stocks have compelling product pipelines and have built up a great head of steam in the past month thanks to the PSY ETF. The post 3 Psychedelics Stocks Getting High Thanks to the Newly Launched PSY ETF appeared first on InvestorPlace.
- 06/15/2021
|
Mind Medicine Stock Might Still Be Worth the Risk Here
- While MNMD stock is incredibly speculative due to uncertainties of psychedelic therapeutics, the need may transcend the risks. The post Mind Medicine Stock Might Still Be Worth the Risk Here appeared first on InvestorPlace.
- 06/11/2021
|
Why Shares of MindMed Dropped 13% in May
- Froth from its uplisting is having an impact.
- 06/09/2021
|
J.R. Rahn Steps Down As MindMed CEO
- Mind Medicine Inc. (NASDAQ:MNMD), more commonly known as MindMed, has announced co-founder and chief executive J.R. Rahn is stepping down from his leadership role, effective immediately.
- 06/09/2021
|
MindMed Announces Chief Executive Officer Transition
- NEW YORK, June 9, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Rahn, the Company's co-founder and chief executive officer, is stepping down as chief executive officer and a director, and that its chief development officer, Robert Barrow, will assume the position of chief executive officer with immediate effect.
- 06/09/2021
|
Stockwatch: MindMed Is Added To The MSCI Small Cap Canada Index
- Mind Medicine is a leading psychedelic pharmaceutical company and the first to be publicly listed. On Thursday, it became the first NEO-listed company to be included in an MSCI Index.
- 05/30/2021
|
NEO Exchange Announces Eligibility In MSCI Indexes
- TORONTO--(BUSINESS WIRE)-- #MSCI--MSCI Inc. now recognizes NEO as an eligible market for inclusion in MSCI Indexes under the MSCI Global Investable Market Indexes Methodology.
- 05/28/2021
|
MindMed announces shareholder Meeting Results
- NEW YORK, May 27, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) ("MindMed" or the "Company") is pleased to announce that each of the resolutions put before the annual and special meeting of shareholders held today (the "Meeting") was passed by the requisite majority of shareholders. As described in the Company's management information circular dated April 19, 2021 (the "Circular"), Jamon Alexander Rahn, Miriam Halperin Wernli, Stephen Hurst, Perry Dellelce, Bruce Linton and Brigid Makes were re-elected as directors of the Company.
- 05/27/2021
|
Mind Medicine Stock Is Not a Trip To Take Just Yet
- Psychedelic drugs may eventually be a big market. However, investors in MNMD stock may be getting in a little too early.
- 05/27/2021
|
MindMed and Liechti Lab in Basel Switzerland Publish First Pharmacogenetic Data on LSD to Help Guide Personalized Dosing
- NEW YORK, May 26, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, announced today the publication of the first pharmacogenetic data on LSD to help personalize dosing. The study results from a pooled secondary analysis of four Phase 1 studies that each used a randomized, double-blind, placebo-controlled, crossover design and were conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland.
- 05/26/2021
|
MindMed Collaborates with Nextage Therapeutics for Brain Targeting Liposome System
- MindMed (NASDAQ: MNMD) and Israel-listed Nextage Therapeutics have entered into an exclusive collaborative development program to optimize the delivery of certain psychedelic drug candidates. The agreement utilizes Nextage's Brain Targeting Liposome System (BTLS) delivery technology.
- 05/24/2021
|
7 Cheap Stocks to Buy Now Under $10
- While no one likes to see red ink on their portfolio, a key benefit is that you now have more choices regarding cheap stocks to buy. The post 7 Cheap Stocks to Buy Now Under $10 appeared first on InvestorPlace.
- 05/24/2021
|
MindMed Announces Launch of Collaboration with Nextage Therapeutics' Brain Targeting Liposome System
- NEW YORK, May 24, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading clinical stage psychedelic medicine company, and Nextage Therapeutics (TASE: NXTG), an Israeli innovative drug development company, announce the execution of a Memorandum of Understanding (the "MOU") regarding the launch of an exclusive collaborative development program to optimize the delivery of certain psychedelic drug candidates, leveraging Nextage's proprietary Brain Targeting Liposome System (BTLS) delivery technology, for which it has an exclusive license. MindMed and Nextage will initially collaborate to optimize the delivery of drug products based on noribogaine, and ultimately other ibogaine derivatives, and will share development costs and intellectual property arising from the collaboration.
- 05/24/2021
|
Why MindMed stock doubled in one day - JR Rahn
- (Kitco News) - The day MindMed listed on the NASDAQ in late April, the share price more than doubled in one day from $2.73 a share to $5.80.
- 05/21/2021
|
The Jury's Still Out on Psychedelics Play MindMed Stock
- It has a shot of finding success. Yet, said success remains many years away.
- 05/20/2021
|
MindMed To Conduct The First Modern Research On Mescaline In Switzerland
- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), announced Thursday that it had obtained authorization from the local Swiss ethics committee to conduct the first clinical trial on mescaline. What Happened The psychedelic medicine biotech company noted that the study will examine the effects of various “doses of mescaline and the role of the serotonin 5-HT2A receptor in mescaline-induced altered state of consciousness.
- 05/20/2021
|
MindMed Announces the Approval of Mescaline Study
- BASEL, Switzerland, May 20, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ), a leading clinical stage psychedelic medicine company, announced today the approval by the local Swiss ethics committee of the first clinical trial evaluating the acute effects of different doses of mescaline and the role of the serotonin 5-HT2A receptor in mescaline-induced altered states of consciousness (MDR-Study). The study will be conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland, and is planned to start this month.
- 05/20/2021
|
The Chopra Foundation and MindMed Enter Into Letter of Intent to Partner on the Future of Psychedelic Medicines & Mental Wellbeing
- NEW YORK, May 18, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) ("MindMed" or the "Company"), a leading clinical stage psychedelic medicine company, today announced it has entered into a letter of intent to partner with The Chopra Foundation to educate and build public awareness around the use of psychedelic medicines to treat mental illness, remove outdated stigmas, and ultimately research mental wellbeing approaches that can be used in psychedelic related psychotherapy. The two organizations plan to design and conduct research together surrounding altered states of consciousness, psychedelic psychotherapy, and their overall impact on mental wellbeing.
- 05/18/2021
|
Strong Cash Balance Should Provide a Foundation for MindMed Stock
- Now that it has joined the Nasdaq Exchange, MNMD stock will have its ups and downs but firm financials should instill shareholder confidence. The post Strong Cash Balance Should Provide a Foundation for MindMed Stock appeared first on InvestorPlace.
- 05/18/2021
|
MindMed Stock Moves Higher After Finalizing Generalized Anxiety Disorder As Initial Indication For LSD Trial
- After receiving Type C Meeting Responses from the FDA, MindMed (NASDAQ: MNMD) has selected Generalized Anxiety Disorder as an initial indication for its Project Lucy, evaluating LSD. The company is on target to formally submit its Investigational New Drug (IND) application for Project Lucy in Q3 and expects to launch its Phase 2b trial after that in Q4 2021.
- 05/17/2021
|
Penny Stocks On Robinhood For You May 2021 Watch List
- Robinhood penny stocks to watch for the next half of May The post Penny Stocks On Robinhood For You May 2021 Watch List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/16/2021
|
MindMed Announces Appointment of Dr. Sarah Y. Vinson as Additional Director
- NEW YORK, May 14, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) ("MindMed" or the "Company") is pleased to announce that it has appointed Dr. Sarah Y. Vinson as a director of the Company and a member of its audit committee, effective immediately.
- 05/14/2021
|
MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD ($194m CAD) to Execute on Diverse Clinical Pipeline
- NEW YORK, May 14, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. ("MindMed'' or the "Company") (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, has announced its quarterly financial results for the quarter ended March 31, 2021. Q1 2021 Financial Highlights (in USD) Total assets as of March 31, 2021 were $201 million, including $160 million in cash Net Cash Used in Operating Activities (Total Cash Burn) of $10 million for the quarter ended March 31, 2021 Net and comprehensive loss of $14 million for the three months ended March 31, 2021 Q1 2021 Business Highlights MindMed closed its acquisition of HealthMode, a leading machine learning digital medicine company, adding Bradford Cross as Chief Technology Officer to lead Albert and Dr. Daniel R Karlin as Chief Medical Officer MindMed began the first-ever clinical trial combining MDMA and LSD in collaboration with UHB Liechti Lab MindMed closed an upsized financing of $92 million CAD ($73 million USD) MindMed closed a subsequent private placement of $19.5 million CAD ($15.4 million USD) MindMed expanded its Microdosing Division adding a groundbreaking study evaluating LSD Microdosing through next-gen digital clinical markers MindMed added Chief Development Officer, Robert Barrow, with FDA Phase 2 Psilocybin clinical trial experience MindMed signed partnership with Swiss psychedelic drug discovery startup MindShift Compounds AG, expanding its development pipeline and IP portfolio with next-gen psychedelic and empathogenic compounds MindMed's LSD neutralizer study began in collaboration with UHB Liechti Lab MindMed added Stanford University Pritzker Professor of Psychiatry and Behavioral Sciences, Dr. Robert Malenka as Chair of its Scientific Advisory Board MindMed announced Its Inclusion in FTSE Russell Indexes Breakdown of Operating Activities Net cash provided through financing activities - $90 million Net cash used in operating activities - $10 million Net cash used for the acquisition of HealthMode - $0.5 million (primarily a stock deal) Management Update & Earnings Call Management will provide updates on its clinical pipeline status and a review of its Q1 2021 financials.
- 05/14/2021
|
EXCLUSIVE: MindMed CEO Talks Mission To 'Discover, Develop And Deploy' Psychedelics
- Mind Medicine Inc (NASDAQ: MNMD) was started to address mental wellness, CEO and co-founder J.R. Rahn told Benzinga's Global Small Cap Conference Thursday.
- 05/13/2021
|
MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development
- NEW YORK, May 13, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic-inspired medicine company has appointed Peter Mack PhD as Vice President of Pharmaceutical Development. As MindMed progresses it's Discover and Develop efforts for multiple commercial clinical programs including LSD and an ibogaine derivative, 18-MC, Peter will lead MindMed's product development activities across its entire portfolio of investigational drugs.
- 05/13/2021
|
7 of the Best Pharma Stocks to Buy Now
- As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year. The post 7 of the Best Pharma Stocks to Buy Now appeared first on InvestorPlace.
- 05/11/2021
|
MindMed Announces Project Angie, Targeting the Treatment of Pain with Psychedelics
- NEW YORK, May 5, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. ("MindMed" or the "Company") (NASDAQ: MNMD) (NEO: MMED), (DE: MMQ), a leading psychedelic-inspired medicine company announces the launch of its Project Angie to advance the development of psychedelics, including LSD, to treat pain conditions. MindMed is currently exploring two primary clinical indications for the treatment of pain.
- 05/05/2021
|
When Will The Selling Pressure In These 2 Hot Stocks End?
- On April 29, shares of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) hit a wall of resistance at the $4.30 level. Since then, they have been in a freefall.
- 05/04/2021
|
7 Runaway Growth Stocks That Could Be the Next Tesla
- Investors searching for Tesla-like price appreciation should consider these seven growth stocks for real returns. The post 7 Runaway Growth Stocks That Could Be the Next Tesla appeared first on InvestorPlace.
- 05/04/2021
|
Is It Time to Sell These 3 Stocks?
- It may be time to sell GameStop Corp. (NYSE: GME), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), and Archer-Daniels-Midland Company (NYSE: ADM) and the reasons why will be outlined below. On Jan 28, Reddit favorite GameStop reached $483 a share.
- 05/03/2021
|
MindMed Stock Hits A Wall Of Resistance
- Shares of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) have hit a wall of resistance at the $4.30 level. This has put a top on the stock.
- 04/30/2021
|
2 Psychedelic Stocks With 10X ‘Shroom Boom' Potential
- Remember when marijuana used to be taboo? Back when Cheech & Chong – a comedy duo who tapped into the height of the cultural weed zeitgeist during the ‘70s – pushed the envelope to further their drug-fueled counterculture movement, weed smokers were still mostly marginalized.
- 04/30/2021
|
Psychedelics Medicine Company MindMed Makes Nasdaq Debut
- MindMed CEO J.R. Rahn spoke to Cheddar about the psychedelic mental health therapy company taking the big step forward going public on the Nasdaq exchange.
- 04/27/2021
|
How to buy Mind Medicine (MindMed): top platforms to trade MNMD
- Mind Medicine (NASDAQ: MNMD) is a psychedelic medicine biotechnology company that started trading on the Nasdaq exchange on Tuesday. MNMD stock is no stranger to the public exchange as shares of Mind Medicine have been listed on the OTC exchange under the ticker “MMEDF”.
- 04/27/2021
|
MNMD Stock: A MindMed Buzz Kill as the Psychedelic Shares Tank on First Day of Trading
- MindMed (MNMD) stock isn't doing so hot with shares taking a beating on the first day of trading at their new home on the Nasdaq. The post MNMD Stock: A MindMed Buzz Kill as the Psychedelic Shares Tank on First Day of Trading appeared first on InvestorPlace.
- 04/27/2021
|
MindMed Stock Climbs In Nasdaq Debut As Psychedelics Follow Pot's Path To Mainstream
- MindMed stock rose in its Nasdaq listing debut on Tuesday, making it the latest psychedelic drug developer to land on a major U.S. exchange. The post MindMed Stock Climbs In Nasdaq Debut As Psychedelics Follow Pot's Path To Mainstream appeared first on Investor's Business Daily.
- 04/27/2021
|
Psychedelics Stock MindMed Debuts On Nasdaq
- Mind Medicine Inc. (NASDAQ:MNMD) commenced trading its subordinate voting shares on The Nasdaq Capital Market Tuesday, under the ticker symbol “MNMD,” as previously announced. The psychedelic medicine biotech company said it will continue to list on the Neo Exchange Inc. under the symbol “MMED,” while subordinate voting shares will transform from the OTCQB under the symbol “MMEDF” to “MNMD.
- 04/27/2021
|
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
- So what did the stock market do today? All eyes were on Tesla stock as it set a new record and MNMD stock ahead of its listing.
- 04/26/2021
|
MindMed Surges Ahead Of Nasdaq Debut
- Clinical-stage psychedelic medicine and biotech company Mind Medicine Inc (OTC:MMEDF), also known as MindMed, is surging again Monday ahead of its Nasdaq debut. The company's mission is "to discover, develop and deploy psychedelic inspired medicines and therapies to address addiction and mental illness," according to CEO J.R.
- 04/26/2021
|
MNMD Stock: 9 Things to Know Before MindMed Hits the Nasdaq on April 27
- As MNMD stock gets ready for its Nasdaq uplisting, the company is seeing rapid gains pushing its price to new highs. The post MNMD Stock: 9 Things to Know Before MindMed Hits the Nasdaq on April 27 appeared first on InvestorPlace.
- 04/26/2021
|
MMEDF Stock: 7 Things to Know About Psychedelic Biotech MindMed Ahead of Its Nasdaq Listing
- MindMed (MMEDF) stock was getting high on Friday as the penny stock prepares for an uplisting to the Nasdaq Exchange from the OTC Markets. The post MMEDF Stock: 7 Things to Know About Psychedelic Biotech MindMed Ahead of Its Nasdaq Listing appeared first on InvestorPlace.
- 04/23/2021
|
